Evidence map›Paper›PMID 42284251›Full record

SynthesisOncology2026

FLAG-Based versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Mohammed Abdulgayoom, Soha Aboukhalaf, Mahmoud Osman, Nada H Soliman, Samreen Mumtaz Rahmoon, Marrita Rabadi, Nuha Fituri, Abdulrahman F Al-Mashdali, Rasha Kaddoura, Shehab F Mohamed

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammed AbdulgayoomDepartment of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, mmohammed35@hamad.qa.
Soha AboukhalafDepartment of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
Mahmoud OsmanDepartment of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
Nada H SolimanDepartment of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
Samreen Mumtaz RahmoonDepartment of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
Marrita RabadiCollege of Medicine, Qatar University, Doha, Qatar.
Nuha FituriDepartment of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
Abdulrahman F Al-MashdaliDepartment of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
Rasha KaddouraPharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Shehab F MohamedDepartment of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe standard induction regimen for newly diagnosed acute myeloid leukemia (AML) in eligible patients remains cytarabine-daunorubicin (7+3), although FLAG-based regimens are increasingly used in high-risk disease.

methodsWe performed a PRISMA 2020-compliant systematic review and meta-analysis comparing FLAG-based induction with standard 7+3 in adults with newly diagnosed AML. Five retrospective cohort studies, including 534 patients, were analyzed.

resultsFLAG-based induction was associated with a significantly higher overall response rate than 7+3 (OR: 1.83, 95% CI: 1.03-3.22), without a significant difference in 30-day mortality (OR 0.56, 95% CI: 0.12-2.69) or 60-day mortality (OR: 0.79, 95% CI: 0.29-2.14). Survival outcomes were heterogeneous and could not be pooled: median overall survival (OS) was similar in 1 cohort, whereas 2 studies reported improved OS with FLAG-based induction; disease-free survival/relapse-free survival outcomes were inconsistently reported. FLAG-based induction was associated with higher receipt of consolidation therapy, while bridging to allogeneic transplantation did not differ significantly. Cytogenetic and molecular risk data were variably defined and incompletely reported, precluding reliable pooled subgroup analyses.

conclusionsOverall, FLAG-based induction improves response rates without a clear increase in early mortality or selected reported safety outcomes; however, its impact on survival remains uncertain and appears influenced by post-remission strategies. Prospective randomized trials are needed to better define its role in frontline AML therapy.

Indexed as

7+3 inductionAcute myeloid leukemiaFLAGIntensive chemotherapyMeta-analysisTreatment outcomes

Identifiers

PMID42284251
PMCPMC13436924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.